7-(对甲苯基)庚酸 | 100863-35-2

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 中文名称: 7-(对甲苯基)庚酸
• 英文名称: 7-(p-tolyl)heptanoic acid
• 英文别名: 7-(4-methylphenyl)heptanoic acid
• CAS: 100863-35-2
• 化学式: C₁₄H₂₀O₂
• 分子量: 220.312
• InChiKey: IULVPTNFONBXHK-UHFFFAOYSA-N

物化性质

• 熔点：
  60.5-61 °C
• 沸点：
  152-157 °C(Press: 0.6 Torr)
• 密度：
  1.021±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  16
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  7-(对甲苯基)庚酸 在 草酰氯 作用下， 生成 1-oxo-1-[5-(2-pyridyl)oxazol-2-yl]-7-(p-tolyl)heptane
  参考文献：
  名称：

  Structure−Activity Relationships of α-Ketooxazole Inhibitors of Fatty Acid Amide Hydrolase

  摘要：

  A systematic study of the structure-activity relationships of 2b (OL-135), a potent inhibitor of fatty acid amide hydrolase (FAAH), is detailed targeting the C2 acyl side chain. A series of aryl replacements or substituents for the terminal phenyl group provided effective inhibitors (e.g., 5c, aryl = 1- napthyl, K-i = 2.6 nM), with 5hh (aryl = 3-ClPh, K-i = 900 pM) being 5-fold more potent than 2b. Conformationally restricted C2 side chains were examined, and many provided exceptionally potent inhibitors, of which 11j (ethylbiphenyl side chain) was established to be a 750 pM inhibitor. A systematic series of heteroatoms (O, NMe, S), electron-withdrawing groups (SO, SO2), and amides positioned within and hydroxyl substitutions on the linking side chain were investigated, which typically led to a loss in potency. The most tolerant positions provided effective inhibitors (12p, 6-position S, K-i = 3 nM, or 13d, 2-position OH, K-i = 8 nM) comparable in potency to 2b. Proteome-wide screening of selected inhibitors from the systematic series of > 100 candidates prepared revealed that they are selective for FAAH over all other mammalian serine proteases.

  DOI：

  10.1021/jm061414r
• 作为产物：
  描述：

  (5-羧基戊基)三苯基溴化磷 在 palladium 10% on activated carbon 、 氢气 、 lithium hexamethyldisilazane 作用下， 以 四氢呋喃 、 乙酸乙酯 为溶剂， 反应 21.75h， 生成 7-(对甲苯基)庚酸
  参考文献：
  名称：

  吡咯烷酰胺衍生物作为N-酰基乙醇胺酸酰胺酶（NAAA）抑制剂的合成，生物学评估和结构活性关系（SAR）研究。

  摘要：

  N-酰基乙醇胺酸酰胺酶（NAAA）是参与脂肪酸乙醇酰胺（FAE）降解的关键酶之一，尤其是对于棕榈酰乙醇酰胺（PEA）而言。NAAA的药理学阻断作用可恢复PEA水平，从而在炎症和疼痛的治疗中提供治疗益处。在当前的工作中，我们显示了吡咯烷酰胺衍生物作为NAAA抑制剂的结构-活性关系（SAR）研究。检查了吡咯烷酰胺的末端苯基的一系列芳族取代基或取代基。SAR数据表明，较小的亲脂性3-苯基取代基对于最佳效用是优选的。构象柔性的接头增加了吡咯烷酰胺衍生物的抑制能力，但降低了其对脂肪酸酰胺水解酶（FAAH）的选择性。构象上受限的接头没有增强抑制剂对NAAA的效力，但是改善了对FAAH的选择性。开发了几种低微摩尔有效的NAAA抑制剂，其中包括带有刚性4-苯基肉桂酰基的4g。透析和动力学分析表明4g通过竞争和可逆的机制抑制NAAA。此外，4g在脂多糖（LPS）诱导的急性肺损伤（ALI）模型中显示出较高的抗

  DOI：

  10.1039/c8md00432c

文献信息

• TRICYCLIC INHIBITORS OF FATTY ACID AMIDE HYDROLASE
  申请人：Boger Dale L.

  公开号：US20100216750A1

  公开（公告）日：2010-08-26

  A series of substituted oxazole compounds having an alpha keto side chain at the 2 position and an aromatic, heteroaromatic or heterocycle substituent at the 5 position are disclosed. These compounds exhibit inhibition of fatty acid amid hydrolase and arc useful for treatment of malconditions involving that enzyme.

  本发明揭示了一系列取代的噁唑化合物，其中在2位具有α-酮基侧链，在5位具有芳香、杂芳或杂环取代基。这些化合物表现出脂肪酸酰胺水解酶的抑制作用，并且对于治疗涉及该酶的恶性状况是有用的。
• Polyhydroxyalkanoate, process for preparing the same, and resin composition containing the polyhydroxyalkanoate
  申请人：Fukui Tatsuki

  公开号：US20060079662A1

  公开（公告）日：2006-04-13

  A novel polyhydroxyalkanoate having a monomer unit represented by the formula (1), the unit having a carboxyl group substituting a ring structure at the end of side chain, obtainable by oxydizing vinyl or methyl group substituting a ring structure at the end of the side chain. The polyhydroxyalkanoate has high thermal stability, charge stablity, a high charge amount, improved dispersibility and biodegradability together, and therefore, suitable for resin moldings, and binders and charge controlling agents for toners used in the electrophotographic process.

  一种新型聚羟基烷酸酯，其单体单元由式(1)表示，单元侧链末端有一个羧基取代的环状结构，可通过将取代侧链末端环状结构的乙烯基或甲基氧化而获得。这种聚羟基烷酸酯具有较高的热稳定性、电荷稳定性、较高的电荷量、较好的分散性和生物降解性，因此适用于树脂成型、电子照相工艺中墨粉的粘合剂和电荷控制剂。
• Huisgen; Vossius, Monatshefte fur Chemie, 1957, vol. 88, p. 517,527
  作者：Huisgen、Vossius

  DOI：——

  日期：——
• LIPOBALANCED LONG CHAIN TESTOSTERONE PRODRUGS FOR ORAL DELIVERY
  申请人：Lipocine Inc.

  公开号：US20140288039A1

  公开（公告）日：2014-09-25

  The present disclosure is drawn to oral pharmaceutical compositions and dosage forms containing select lipobalanced testosterone prodrugs and related methods. In one embodiment of the present invention, an oral pharmaceutical composition for administration to subjects in need of testosterone is provided. The composition comprises a lipobalanced testosterone prodrugs and a pharmaceutically acceptable carrier.
• LIPOBALANCED LONG CHAIN TESTOSTERONE ESTERS FOR ORAL DELIVERY
  申请人：Lipocine Inc.

  公开号：US20190240235A1

  公开（公告）日：2019-08-08

  The present disclosure is drawn to oral pharmaceutical compositions and dosage forms containing select lipobalanced testosterone prodrugs and related methods. In one embodiment of the present invention, an oral pharmaceutical composition for administration to subjects in need of testosterone is provided. The composition comprises a lipobalanced testosterone prodrugs and a pharmaceutically acceptable carrier.